| ID | 10346 |
| Vaccine Name | SCB-2019 |
| Disease Name | COVID-19 |
| Disease Classification | Respiratory |
| Virus Name | SARS-CoV-2 virus |
| Nucleic Acid Content | positive-sense, single-stranded RNA |
| Vaccine Type | Protein subunit |
| Vaccine Status | Phase 3 |
| Manufacturer | Clover Biopharmaceuticals |
| Year of Manufacturing | NA |
| Manufacturing Country | Australia |
| Age | NA |
| Dosage | NA |
| Administration Route | Intramuscular |
| Adjuvant | NA |
| Target Strain | NA |
| Description | Novel recombinant SARSCoV-2 Spike trimer fusion protein |
| Approving Organisation | NA |
| Collaborating Organisation | NA |
| Other Countries | Belgium, Brazil, Colombia, Dominican Republic, Germany, Nepal, Panama, Philippines, Poland |
| Trade Name | NA |
| PMID | NA |
| Clinical Trial ID | NCT04405908 |
| Reference Link | https://extranet.who.int/pqweb/sites/default/files/documents/Status_of_COVID-19_Vaccines_within_WHO_EUL-PQ_evaluation_process-16June2021_Final.pdf |
| Additional Links | https://clinicaltrials.gov/ct2/show/NCT04405908
|